Satu Mustjoki

Research interests

Publications

• Predicting recognition between T cell receptors and epitopes with TCRGP

  PLoS Computational Biology · 2021 · 10.1371/journal.pcbi.1008814

• Somatic Mutations in “Benign” Disease

  New England Journal of Medicine · 2021 · 10.1056/nejmra2101920

• Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

  Cancer Discovery · 2021 · https://doi.org/10.1158/2159-8290.cd-21-0410

• Immunogenomic Landscape of Hematological Malignancies

  Cancer Cell · 2020 · https://doi.org/10.1016/j.ccell.2020.06.002

• Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma

  Haematologica · 2020 · 10.3324/haematol.2019.243626

• Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

  Leukemia · 2019 · 10.1038/s41375-019-0512-y

• Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

  Blood · 2019 · 10.1182/blood.2019002121

• Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia

  Haematologica · 2019 · https://doi.org/10.3324/haematol.2018.214882

• Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30192-x

• Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

  Nature Medicine · 2017 · https://doi.org/10.1038/nm.4336

• Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

  Blood · 2017 · 10.1182/blood-2016-07-728873

• Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

  Leukemia · 2016 · 10.1038/leu.2016.360

• Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3

  Blood · 2014 · 10.1182/blood-2014-04-570101

• Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease

  Nature Genetics · 2014 · https://doi.org/10.1038/ng.3040

• Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia

  Blood · 2013 · https://doi.org/10.1182/blood-2012-12-474577

• STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients

  Blood · 2013 · https://doi.org/10.1182/blood-2013-04-494930

• Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia

  Cancer Discovery · 2013 · https://doi.org/10.1158/2159-8290.cd-13-0350

• STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

  Blood · 2012 · 10.1182/blood-2012-06-435297

• Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1114885

• Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

  Blood · 2011 · 10.1182/blood-2011-02-336685

• Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy

  Blood · 2010 · 10.1182/blood-2009-12-256800

• Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

  Leukemia · 2009 · 10.1038/leu.2009.46

• Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

  Blood · 2008 · https://doi.org/10.1182/blood-2008-02-140665

• VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells

  Blood · 2002 · 10.1182/blood-2002-03-0755

• Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF‐C/D receptor VEGFR‐3

  The EMBO Journal · 2001 · 10.1093/emboj/20.17.4762

Current projects

No projects listed.